Jonathan I. Lieber

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Waltham, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
By:/s/ Stephen Uden, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Jonathan I. Lieber

Form 4 holding Chief Financial Officer

Rallybio Corp

Security class
Common Stock
Shares / value
4,115
Estimated value
$2,823
Report date
23 Feb 2026
Price
$0.6861
Ownership
Direct
Form 4 holding Director

Salarius Pharmaceuticals, Inc.

Security class
Stock Option (right to buy)
Shares / value
20,500
Estimated value
Report date
20 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

APPLIED GENETIC TECHNOLOGIES CORP

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
30 Nov 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Jonathan I. Lieber

3 RLYB

Rallybio Corp

Report period
01 Feb 2023
Transactions
0
Transaction value
$0
Accepted by SEC
01 Feb 2023, 17:29
Role
Chief Financial Officer and Treasurer Exhibit List: Exhibit 24 - Power of Attorney
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .